Trilafon Dekanoat (Perphenazine Decanoate)

What Is Trilafon Dekanoat and What Is It Used For?

Quick Answer: Trilafon Dekanoat is a long-acting injectable antipsychotic containing perphenazine decanoate. It is used for the maintenance treatment of psychoses, including schizophrenia and related disorders, providing sustained symptom control through periodic intramuscular depot injections.

Trilafon Dekanoat contains the active substance perphenazine in the form of perphenazine decanoate, a long-chain fatty acid ester that enables slow, sustained release of the drug from the intramuscular injection site. This depot formulation belongs to the phenothiazine class of first-generation (typical) antipsychotic medications, which have been used in psychiatry for over six decades. The ATC (Anatomical Therapeutic Chemical) classification code is N05AB03, placing it within the phenothiazine antipsychotic group.

The primary indication for Trilafon Dekanoat is the treatment of psychotic disorders, which are characterised by a range of debilitating symptoms including delusions (fixed, false beliefs), hallucinations (perceptions without external stimuli, most commonly auditory), thought disorders (disorganised or fragmented thinking), confusion, impaired consciousness, and psychomotor agitation (excessive, purposeless motor activity). Psychosis can occur in the context of schizophrenia, schizoaffective disorder, and other psychiatric conditions.

The depot formulation is particularly advantageous for patients requiring long-term antipsychotic maintenance therapy. According to meta-analyses published in the Cochrane Database of Systematic Reviews, depot antipsychotics significantly reduce the risk of relapse compared with oral formulations, largely because they eliminate the issue of non-adherence to daily oral medication. This is clinically important because non-adherence to oral antipsychotics is one of the strongest predictors of psychotic relapse and psychiatric hospitalisation.

How Does Trilafon Dekanoat Work?

Perphenazine exerts its antipsychotic effect primarily through blockade of dopamine D2 receptors in the mesolimbic and mesocortical pathways of the central nervous system. The dopamine hypothesis of psychosis, first proposed in the 1960s and supported by extensive research, posits that hyperactivity of dopaminergic neurotransmission in certain brain regions is a key driver of positive psychotic symptoms such as hallucinations and delusions. By blocking D2 receptors, perphenazine reduces this excessive dopaminergic signalling and thereby alleviates psychotic symptoms.

As a phenothiazine compound, perphenazine also has significant blocking activity at muscarinic acetylcholine receptors, alpha-1 adrenergic receptors, histamine H1 receptors, and serotonin receptors. This broad receptor binding profile accounts for both additional therapeutic effects (such as sedation and anxiolysis) and a range of side effects including anticholinergic symptoms, orthostatic hypotension, and weight gain. The pharmacological profile of perphenazine places it as a medium-potency antipsychotic, with somewhat less propensity for extrapyramidal symptoms than high-potency agents such as haloperidol, but greater antipsychotic efficacy than low-potency agents such as chlorpromazine at equivalent doses.

In the depot formulation, perphenazine is esterified with decanoic acid to form perphenazine decanoate. When injected intramuscularly, this ester is slowly hydrolysed by tissue esterases, gradually releasing active perphenazine into the systemic circulation. The solution contains sesame oil as the vehicle, which further slows absorption and contributes to the prolonged duration of action. The result is stable, sustained plasma levels of perphenazine over a period of two to four weeks, avoiding the peak-and-trough fluctuations associated with oral dosing.

What Should You Know Before Receiving Trilafon Dekanoat?

Quick Answer: Trilafon Dekanoat is contraindicated in patients with known allergy to perphenazine, leukopenia/agranulocytosis, or pheochromocytoma. Numerous conditions require careful evaluation before starting treatment, including a history of blood clots, epilepsy, cardiovascular disease, and liver or kidney impairment.

Contraindications

There are absolute contraindications to the use of Trilafon Dekanoat that must be respected without exception. The medication must not be administered to patients with a known hypersensitivity (allergy) to perphenazine, perphenazine decanoate, or any of the excipients in the formulation, including sesame oil and propylparaben (E216). Allergic reactions can range from localised skin reactions to severe systemic responses including angioedema.

Patients with leukopenia (low white blood cell count) or agranulocytosis (dangerously low neutrophil count) must not receive Trilafon Dekanoat, as phenothiazine antipsychotics can further suppress bone marrow function and potentially worsen these conditions to life-threatening levels. A baseline complete blood count should be obtained before initiating treatment. Patients with a history of phenothiazine-induced blood dyscrasias should never be rechallenged with this medication class.

The medication is also contraindicated in patients with pheochromocytoma, a rare neuroendocrine tumour of the adrenal glands. In patients with pheochromocytoma, phenothiazines can paradoxically cause a hypertensive crisis due to their complex effects on catecholamine metabolism and adrenergic receptor blockade.

Warnings and Precautions

A comprehensive medical evaluation is essential before starting Trilafon Dekanoat therapy. The prescribing physician must be informed of all relevant medical history, as numerous conditions require careful risk-benefit assessment and may necessitate dose adjustments, enhanced monitoring, or in some cases, selection of an alternative treatment.

Venous thromboembolism (VTE): All antipsychotic medications, including perphenazine, have been associated with an increased risk of venous thromboembolism, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). Patients with a personal or family history of VTE, obesity, immobility, or other thrombotic risk factors should be carefully evaluated. The European Medicines Agency (EMA) has issued guidance recommending that all modifiable risk factors for VTE be identified and addressed before and during antipsychotic treatment.

Epilepsy and seizure disorders: Phenothiazine antipsychotics lower the seizure threshold, meaning they can increase the likelihood of seizures in susceptible individuals. Patients with a history of epilepsy or seizure disorders require particularly careful monitoring, and concomitant anticonvulsant therapy may need dose adjustment. The prescribing physician should conduct a thorough risk assessment and ensure appropriate seizure prophylaxis is in place.

Cardiovascular considerations: Trilafon Dekanoat requires cautious use in patients with severe atherosclerosis, circulatory failure, or pre-existing cardiovascular disease. The medication can cause orthostatic hypotension (a drop in blood pressure upon standing) through alpha-1 adrenergic receptor blockade, which can be particularly dangerous in elderly patients or those with compromised cardiac function. Furthermore, perphenazine has been associated with QT interval prolongation on electrocardiogram, which increases the risk of potentially fatal cardiac arrhythmias including Torsade de Pointes. A baseline ECG is recommended before starting treatment, and the medication should be used with extreme caution in patients with pre-existing QT prolongation or other cardiac rhythm abnormalities.

Cerebrovascular risk: Observational studies have suggested an increased risk of cerebrovascular adverse events (stroke and transient ischaemic attack) with antipsychotic medications, particularly in elderly patients with dementia-related psychosis. Regulatory agencies including the EMA and the US FDA have issued warnings that antipsychotics are associated with an increased risk of death in this population. Trilafon Dekanoat is not approved for the treatment of dementia-related behavioural disturbances.

Hepatic and renal impairment: Perphenazine is extensively metabolised in the liver and excreted through the kidneys. Patients with liver disease may have impaired drug metabolism, leading to higher plasma levels and increased risk of adverse effects. Similarly, renal impairment can affect drug elimination. Liver function tests and renal function tests should be performed before starting treatment and monitored periodically during therapy.

Oral health considerations: Trilafon Dekanoat can cause significant dry mouth (xerostomia) through its anticholinergic effects. Chronic dry mouth increases the risk of dental caries, gingivitis, and oral candidiasis. Patients should be counselled on the importance of meticulous oral hygiene, regular dental check-ups, and the use of saliva substitutes or sugar-free lozenges to maintain oral moisture.

Pregnancy, Breastfeeding, and Fertility

Pregnancy: The use of Trilafon Dekanoat during pregnancy, particularly during the third trimester, carries the risk of neonatal adverse effects. Newborns exposed to antipsychotic medications in the final weeks of pregnancy may develop symptoms including tremors, muscle rigidity (hypertonia), drowsiness, agitation, breathing difficulties, and feeding problems. These neonatal adaptation symptoms are typically self-limiting but may require medical monitoring and supportive care. The decision to use Trilafon Dekanoat during pregnancy must involve a careful, individualised risk-benefit analysis conducted by a specialist psychiatrist in conjunction with obstetric care providers. Abrupt discontinuation of antipsychotic medication in a pregnant woman with severe psychosis carries its own significant risks.

Breastfeeding: Perphenazine is known to pass into breast milk, although concentrations are generally low. Current evidence suggests that the amounts transferred to a nursing infant at standard therapeutic doses are unlikely to cause clinically significant effects. However, the decision to breastfeed while receiving Trilafon Dekanoat should be made in consultation with the treating physician, who can weigh the benefits of breastfeeding against the potential risks of infant drug exposure and the consequences of interrupting maternal antipsychotic treatment.

Driving and Operating Machinery

Trilafon Dekanoat may significantly impair psychomotor performance and reaction time. The sedative effects, particularly in the period immediately following injection, can affect the ability to drive vehicles and operate machinery safely. Patients should be advised not to drive or engage in activities requiring full alertness until they have established how the medication affects them personally. This is particularly important during the initial dose-finding period and whenever the dose is increased.

How Does Trilafon Dekanoat Interact with Other Drugs?

Quick Answer: Trilafon Dekanoat has clinically significant interactions with many medication classes. Alcohol must never be combined with this medication. Concurrent use with sedatives, opioids, lithium, antihypertensives, and QT-prolonging drugs all require careful medical supervision and potential dose adjustments.

Drug interactions with Trilafon Dekanoat are a critical clinical consideration, as perphenazine affects multiple neurotransmitter systems and has complex pharmacokinetic properties. The interactions described below are well-documented and should guide prescribing decisions. Patients must inform their treating physician and pharmacist of all medications they are taking, including over-the-counter medicines, herbal products, and supplements.

Alcohol interaction: The interaction between Trilafon Dekanoat and alcohol deserves particular emphasis. Alcohol potentiates the central nervous system depressant effects of perphenazine, which can lead to dangerous levels of sedation, respiratory depression, severe hypotension, and loss of consciousness. This interaction is unpredictable in severity and can be life-threatening. Patients receiving Trilafon Dekanoat must completely abstain from alcohol throughout their treatment. Healthcare providers should screen for alcohol use before initiating therapy and provide clear counselling about this absolute contraindication.

Sedatives and hypnotics: Concurrent use of benzodiazepines, Z-drugs (zopiclone, zolpidem), barbiturates, or other sedative-hypnotic agents with Trilafon Dekanoat results in additive central nervous system depression. This combination increases the risk of excessive sedation, falls (particularly in elderly patients), and respiratory compromise. When co-prescribing is clinically necessary, the lowest effective doses should be used, and patients should be closely monitored for signs of excessive sedation.

Opioid analgesics: The combination of perphenazine with opioid analgesics produces enhanced CNS depression through complementary pharmacodynamic mechanisms. Both drug classes depress respiratory drive, and their combination can lead to clinically significant respiratory depression, particularly in opioid-naive patients or those with pre-existing pulmonary disease. When pain management with opioids is required in patients receiving Trilafon Dekanoat, careful titration with close monitoring is essential.

Lithium: The combination of lithium with phenothiazine antipsychotics has been associated with an increased risk of neurotoxicity, which can manifest as confusion, disorientation, coarse tremor, muscle rigidity, ataxia (impaired coordination), and hyperreflexia. This interaction can occur even when lithium serum levels are within the therapeutic range. When lithium and Trilafon Dekanoat are used concurrently, regular monitoring of lithium levels, renal function, and neurological status is mandatory. Patients and caregivers should be educated about the early warning signs of neurotoxicity.

QT-prolonging medications: Perphenazine can prolong the QT interval on electrocardiogram, and concurrent use with other QT-prolonging drugs creates an additive risk of dangerous cardiac arrhythmias. Drugs of particular concern include antiarrhythmics (amiodarone, sotalol, quinidine), certain antibiotics (macrolides, fluoroquinolones), some antidepressants (tricyclics, citalopram), and certain antiemetics (ondansetron, domperidone). The British National Formulary (BNF) recommends ECG monitoring when combining QT-prolonging agents, and clinical judgment should weigh the necessity of the combination against the cardiac risk.

How Is Trilafon Dekanoat Administered?

Quick Answer: Trilafon Dekanoat is given exclusively as a deep intramuscular injection by a healthcare professional. The dosage is individualised by the prescribing physician. Special technical precautions are required: the syringe and needle must be completely dry, and a filter needle should be used when drawing up the solution.

Trilafon Dekanoat must only be administered by qualified healthcare professionals experienced in the use of depot antipsychotic injections. The medication is given as a deep intramuscular (IM) injection, typically into the gluteal muscle (upper outer quadrant of the buttock) or the deltoid muscle. Subcutaneous or intravenous administration must never be attempted. The choice of injection site should be rotated between visits to minimise local tissue reactions and injection site discomfort.

Dosage Determination

Treatment with Trilafon Dekanoat is usually initiated only after the patient has been stabilised on oral perphenazine, confirming both efficacy and tolerability before committing to the long-acting depot formulation. This approach allows dose titration in a more controllable manner, as oral perphenazine has a much shorter half-life and its effects can be more readily adjusted. The transition from oral to depot formulation requires careful calculation of equivalent doses, and there may be a period of overlap where both oral and depot preparations are administered to ensure continuous therapeutic coverage.

The injection interval is typically every two to four weeks, although this can vary between patients. The goal is to maintain stable plasma perphenazine concentrations within the therapeutic range throughout the dosing interval. Some patients may require adjustments to the dose or interval based on their clinical response and tolerability. It is important that patients attend all scheduled injection appointments to maintain consistent antipsychotic coverage and prevent relapse.

Technical Administration Requirements

Trilafon Dekanoat has specific technical requirements that distinguish it from many other injectable medications. These precautions are critical for ensuring proper drug delivery and preventing precipitation of the formulation:

• Dry syringe and needle: The syringe and injection needle must be completely dry before use. Any moisture (water, saline, or residual cleaning solutions) coming into contact with the oily perphenazine decanoate solution will cause precipitation, rendering the injection potentially ineffective and possibly unsafe. Disposable, factory-sealed syringes and needles are preferred.
• Filter needle for drawing up: A filter needle should be used when drawing the solution from the vial or ampoule. This removes any particulate matter or glass fragments that may have entered the solution during the opening of the ampoule.
• Change needle before injecting: After drawing up the solution with the filter needle, a fresh standard injection needle should be attached for the actual intramuscular injection. This ensures clean, atraumatic injection and prevents tissue irritation from a dulled or contaminated needle.
• Injection technique: The injection should be given slowly and deeply into the muscle mass. Aspiration before injection is recommended to ensure the needle is not positioned within a blood vessel. After injection, gentle pressure should be applied to the site without massaging, as vigorous rubbing can alter the absorption profile of the depot.

What Are the Side Effects of Trilafon Dekanoat?

Quick Answer: Like all antipsychotic medications, Trilafon Dekanoat can cause side effects. Common effects include drowsiness, movement disorders (extrapyramidal symptoms), and dry mouth. Serious but rare effects include neuroleptic malignant syndrome, blood disorders (agranulocytosis), cardiac arrhythmias, and blood clots. Not everyone experiences side effects, and many are dose-related and manageable.

All medications carry the potential for adverse effects, and Trilafon Dekanoat is no exception. The side effect profile of perphenazine reflects its broad pharmacological activity at multiple receptor types in the central and peripheral nervous systems. It is important to understand that not every patient will experience side effects, and many effects are dose-dependent, meaning they can often be managed through dose adjustment. Patients should report any new or worsening symptoms to their healthcare provider promptly.

The following side effects are categorised by frequency according to the standard regulatory convention used by the European Medicines Agency (EMA): common (affects up to 1 in 10 patients), uncommon (affects up to 1 in 100 patients), rare (affects up to 1 in 1,000 patients), and frequency not known (cannot be estimated from available data).

Extrapyramidal Symptoms (EPS) in Detail

Extrapyramidal symptoms are among the most clinically significant adverse effects of first-generation antipsychotics like perphenazine. These movement disorders arise from dopamine D2 receptor blockade in the nigrostriatal pathway of the brain, which normally coordinates smooth, voluntary muscle movements. Understanding the different types of EPS is important for both patients and caregivers:

• Acute dystonia: Sudden, sustained muscle contractions causing abnormal postures, typically occurring within hours to days of starting treatment or dose increases. Can affect the neck (torticollis), jaw (trismus), tongue, eyes (oculogyric crisis), or trunk. Treated acutely with anticholinergic agents such as procyclidine or biperiden.
• Akathisia: A distressing subjective sense of inner restlessness and an inability to sit or stand still, often accompanied by observable fidgeting or pacing. Akathisia can be confused with psychotic agitation and, if misidentified, may lead to inappropriate dose increases that worsen the condition. Beta-blockers (propranolol) or benzodiazepines may be helpful.
• Parkinsonism (drug-induced): A syndrome resembling Parkinson's disease, characterised by tremor (typically a rhythmic "pill-rolling" tremor at rest), rigidity (increased muscle tone), bradykinesia (slowness of movement), and postural instability. Usually responds to dose reduction or the addition of an anticholinergic agent.
• Tardive dyskinesia: Involuntary, repetitive, purposeless movements, most commonly affecting the orofacial region (lip smacking, chewing movements, tongue protrusion), but potentially involving the limbs and trunk. Tardive dyskinesia is a late-onset complication that may emerge after months or years of antipsychotic treatment and can be irreversible in some cases. Risk increases with cumulative dose and duration of treatment, advanced age, and female sex.

Metabolic and Endocrine Effects

Perphenazine, like other antipsychotic medications, can affect endocrine function through its dopamine-blocking effects on the tuberoinfundibular pathway. Dopamine normally inhibits prolactin release from the anterior pituitary gland, so dopamine receptor blockade leads to hyperprolactinaemia (elevated prolactin levels). Clinical manifestations can include gynecomastia (breast tissue enlargement in both sexes), galactorrhea (inappropriate milk production), menstrual irregularities including amenorrhea (absent periods), and sexual dysfunction (decreased libido, erectile dysfunction). Long-standing hyperprolactinaemia has been associated with decreased bone mineral density, which may increase the risk of osteoporosis and fractures over time.

Weight gain, although typically less pronounced with perphenazine than with many second-generation antipsychotics, can nonetheless occur and should be monitored. The World Health Organization (WHO) recommends regular monitoring of body weight, waist circumference, blood glucose, and lipid profiles in patients receiving long-term antipsychotic treatment, regardless of the specific agent used.

Cardiovascular Effects

The cardiovascular effects of Trilafon Dekanoat warrant careful attention. Orthostatic hypotension, caused by alpha-1 adrenergic receptor blockade, is most likely to occur during the initial period of treatment or following dose increases. Patients should be advised to rise slowly from sitting or lying positions and to report symptoms such as dizziness, lightheadedness, or near-fainting. The QT prolongation associated with perphenazine carries a risk of potentially fatal ventricular arrhythmias, particularly in patients with pre-existing cardiac conditions, electrolyte imbalances (hypokalaemia, hypomagnesaemia), or those taking other QT-prolonging medications concurrently.

How Should Trilafon Dekanoat Be Stored?

Quick Answer: Trilafon Dekanoat should be stored at a temperature below 25 degrees Celsius. The medication should be kept in its original packaging to protect it from light. As with all medications, it should be stored out of the reach and sight of children.

Proper storage of Trilafon Dekanoat is essential to maintain the stability, efficacy, and safety of the formulation. The oily solution for injection is sensitive to environmental conditions, and improper storage can lead to degradation of the active substance or changes in the physical properties of the solution that could affect its suitability for injection.

The medication must be stored at a temperature below 25 degrees Celsius (77 degrees Fahrenheit). It should not be frozen, as freezing can alter the physical characteristics of the oily vehicle and potentially affect drug release after injection. The product should be kept in its original packaging until use to protect it from light, as perphenazine decanoate can undergo photodegradation when exposed to direct light for prolonged periods.

Before administration, the solution should be visually inspected for any particulate matter, discolouration, or precipitation. A clear, oil-based solution of appropriate colour is expected. If the solution appears cloudy, discoloured, or contains visible particles, it should not be used and should be returned to the pharmacy for disposal. The expiry date printed on the packaging must be checked before each administration, and expired medication must never be used.

Healthcare facilities are responsible for maintaining appropriate storage conditions and ensuring proper stock rotation (first-expiry, first-out principle). Patients do not typically store Trilafon Dekanoat at home, as it is administered in clinical settings. However, if a patient is provided with the medication to bring to an appointment, they should be instructed to keep it at room temperature, out of direct sunlight, and to transport it in an insulated bag if ambient temperatures are high.

Disposal of unused or expired Trilafon Dekanoat should follow local regulations for pharmaceutical waste. The medication should not be disposed of in household waste or flushed down the toilet, as the oily formulation can be harmful to the environment. Patients and healthcare providers should utilise designated pharmaceutical waste collection points.

What Does Trilafon Dekanoat Contain?

Quick Answer: Trilafon Dekanoat contains the active substance perphenazine decanoate (108 mg/ml, equivalent to 78 mg perphenazine per ml) in a sesame oil vehicle, with propylparaben (E216) as a preservative. Patients with known allergies to sesame or paraben-containing products should inform their physician.

Each millilitre of Trilafon Dekanoat solution for injection contains 108 mg of perphenazine decanoate, which is equivalent to approximately 78 mg of perphenazine. The decanoate ester form is a prodrug that is hydrolysed after intramuscular injection to release active perphenazine into the systemic circulation over a sustained period.

Active Substance

Perphenazine decanoate is formed by esterification of perphenazine with decanoic acid (capric acid), a ten-carbon saturated fatty acid. This esterification dramatically increases the lipophilicity (fat solubility) of the molecule, allowing it to be dissolved in an oily vehicle and creating a depot within the muscle tissue from which the active drug is slowly released. The molecular weight of perphenazine decanoate is higher than that of free perphenazine, which accounts for the difference between the total perphenazine decanoate content (108 mg/ml) and the equivalent perphenazine content (78 mg/ml).

Excipients

Sesame oil: The primary excipient in Trilafon Dekanoat is sesame oil (Sesamum indicum), which serves as the oily vehicle for the solution. Sesame oil is widely used in pharmaceutical depot formulations because of its excellent biocompatibility, stability, and ability to sustain drug release over extended periods. However, sesame oil is derived from sesame seeds, and patients with known sesame allergy may be at risk of allergic reactions. While severe sesame allergy is relatively uncommon, it should be specifically enquired about before administering Trilafon Dekanoat. Cross-reactivity with other plant-derived oils is possible but has not been systematically studied.

Propylparaben (E216): Propyl parahydroxybenzoate (propylparaben) is included as an antimicrobial preservative to prevent microbial contamination of the multi-dose formulation. Parabens are widely used in pharmaceutical and cosmetic products, but they can cause allergic reactions in susceptible individuals. Hypersensitivity reactions to parabens can manifest as contact dermatitis, urticaria, or, rarely, anaphylaxis. Patients with a known history of paraben sensitivity should inform their healthcare provider. The potential for delayed-type hypersensitivity reactions (typically localised skin reactions at the injection site) should be considered if unexplained injection site reactions occur.

Frequently Asked Questions

References

Editorial Team